Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Active, not recruiting · Phase 1 · NCT04526691

Conditions: Advanced or Metastatic NSCLC

Research payments reported, 2025: $99,649
U.S. investigators named: 5
Sites paid: 5
Planned or actual enrollment: 145

About the trial

Sponsor: Daiichi Sankyo (with Merck Sharp & Dohme LLC)
Tested: Datopotamab deruxtecan (drug), KEYTRUDA® (drug), Carboplatin (drug), Cisplatin (drug)
Dates: Started 2020-09-15; completion 2026-12-31
Results posted: Not yet

This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.

From ClinicalTrials.gov, last updated 2026-05-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $99,649 in research payments for this study in 2025 (13 payments).

Products named: Datroway

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Johns Hopkins University $56,255
Mayo Clinic, FL $21,331
City of Hope National Medical Ctr $12,559
Mayo Clinic Hospital Rochester, MN $9,055
Mayo Clinic Hospital, AZ $450

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it